Actively Recruiting
Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy
Led by Nanfang Hospital, Southern Medical University · Updated on 2024-03-15
374
Participants Needed
5
Research Sites
140 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Immune checkpoint inhibitors have ushered in a new era of cancer treatment, bringing significant survival benefits to patients. However, some patients have accelerated tumor growth in the early stage of immunotherapy, called hyperprogression. The quality of life of patients with hyperprogression is seriously reduced, and there is no effective treatment at present, and the prognosis is extremely poor. Therefore, early identification of high-risk groups of hyperprogression is the key to prevent hyperprogression. However, there are no effective biomarkers to predict hyperprogression. By sequencing, proteomics and metabolomics analysis of clinical tissue and blood samples, we found that the level of SAA1 was significantly increased in patients with hyperprogression, and SAA1 was an effective marker for predicting hyperprogression in pan-cancer. We planned to conduct a multicenter, prospective cohort study to verify the reliability of SAA1 as a marker for predicting hyperprogression of immunotherapy in pan-cancer patients.
CONDITIONS
Official Title
Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Over 18 years of age
- Voluntarily sign informed consent
- Pathological diagnosis of nasopharyngeal carcinoma, head and neck tumor, lung cancer, breast cancer, stomach cancer, colorectal cancer, glioma, esophageal cancer, liver cancer, bile duct cancer, cervical cancer, prostate cancer, bladder cancer, or other malignant tumors
- Need to be treated with immune checkpoint inhibitors
- ECOG performance status score of 0 or 1
You will not qualify if you...
- Contraindications to immunotherapy
- Presence of other tumors (except cured basal cell or squamous cell skin cancer, or cervical cancer in situ removed)
- Serious coexisting medical conditions that pose unacceptable risk or affect trial adherence, such as unstable heart disease requiring treatment, chronic hepatitis, kidney disease, poor disease status, uncontrolled diabetes (fasting blood glucose > 1.5 times upper limit of normal), or mental illness
- Considered unsuitable for participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Nanfang hospital, Southern medical university
Guangzhou, Guangdong, China, 510515
Actively Recruiting
2
Fujian Provinical Hospital
Fuzhou, China
Not Yet Recruiting
3
Huizhou Central People's Hospital
Huizhou, China
Not Yet Recruiting
4
Jieyang people's hospital
Jieyang, China
Not Yet Recruiting
5
Meizhou People's Hospital, Meizhou Academy of Medical Sciences Meizhou
Meizhou, China
Not Yet Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here